Traumakine (IFN beta-1a) / Maruishi Pharma, Faron Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Traumakine (IFN beta-1a) / Faron Pharma, Maruishi Pharma
Faron Pharma_COVID_T: Faron Pharmaceuticals drug accepted to global pneumonia programme

Not yet recruiting
3
0
Asia-Pacific, Europe and North America
Traumakine
Faron Pharma, Maruishi Pharma
Coronavirus (COVID-19)
 
 
Faron Pharma_COVID_Traumakine: Faron Pharmaceuticals drug accepted to global pneumonia programme

Recruiting
3
0
Asia-Pacific, Europe and North America
Traumakine
Faron Pharma, Maruishi Pharma
Coronavirus (COVID-19)
 
 
INTEREST, NCT02622724 / 2014-005260-15: Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

Terminated
3
301
Europe, RoW
Interferon beta-1a, FP-1201-lyo, Traumakine, ATC code L03AB07, Placebo, FP-1201-lyo Placebo
Faron Pharmaceuticals Ltd, Seventh Framework Programme
Respiratory Distress Syndrome, Adult
05/18
05/18

Download Options